Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelicapavir - Enanta Pharmaceuticals

Next Previous
Drug Profile

Zelicapavir - Enanta Pharmaceuticals

Alternative Names: EDP-938; EP 023938

Latest Information Update: 02 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Amines; Antivirals; Benzene derivatives; Benzodiazepines; Fluorocarbons; Ketones; Morpholines; Oxadiazoles; Pyridines; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 24 Nov 2025 Efficacy and adverse events data from a the phase IIb RSVHR trial in Respiratory syncytial virus infections released by Enanta Pharmaceuticals
  • 31 Oct 2025 Updated efficacy data from the phase II RSVPEDs trial in Respiratory syncytial virus infections released by Enanta Pharmaceuticals, in October 2025
  • 23 Jun 2025 Enanta Pharmaceuticals completes the phase-IIb RSVHR trial in Respiratory syncytial virus infections (In adults, In the elderly) in Taiwan, Spain, South Africa, Slovakia, Puerto Rico, Poland, Netherlands, Malaysia, Israel, Czech Republic, Brazil, Bulgaria, Argentina, and USA (PO) (NCT05568706) (EudraCT2022-002215-29)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top